Ann: Creso Pharma and LGC Capital announce Strategic Alliance, page-14

I don't think they've made the connection LL...

It's my belief that the meteoric rise of both AC8 and CAN are centred around the Australian licenses (export for CAN in particular).....not that either of them have a product ready for sale yet in Australia, but seemingly, few holders do enough research....so they buy on the 'promise' of products etc.

I feel that with the Mernova deal (share issue), the CPH share price will be held back somewhat, the caveat of course, is whether they can turn their "imminent launch" into imminent revenue. I figure whichever company can show investors the money in the immediate term, will benefit with longer sustained SP runs.